Screening and management of cardiovascular risk factors in systemic lupus erythematosus: Recommendations for clinical practice based on the literature and expert opinion
| Affiliation auteurs | !!!! Error affiliation !!!! |
| Titre | Screening and management of cardiovascular risk factors in systemic lupus erythematosus: Recommendations for clinical practice based on the literature and expert opinion |
| Type de publication | Journal Article |
| Year of Publication | 2015 |
| Auteurs | Arnaud L., Mathian A., Adoue D., Bader-Meunier B., Baudouin V., Belizna C., Bonnotte B., Boumedine F., Chaib A., Chauchard M., Chiche L., Daugas E., Ghali A., Gobert P., Gondran G., Guettrot-Imbert G., Hachulla E., Hamidou M., Haroche J., Hervier B., Hummel A., Jourde-Chiche N., Korganow A-S, Kwon T., Le Guern V., Le Quellec A., Limal N., Magy-Bertrand N., Marianetti-Guingel P., Martin T., N. Silva M, Meyer O., Miyara M., Morell-Dubois S., Ninet J., Papo T., Pennaforte J-L, Polomat K., Pourrat J., Queyrel V., Raymond I., Remy P., Sacre K., Schmidt J., Sibilia J., Viallard J-F, A. Brabant V, Wahl D., Bruckert E., Amoura Z., FLEUR, Syn CReference |
| Journal | REVUE DE MEDECINE INTERNE |
| Volume | 36 |
| Pagination | 372-380 |
| Date Published | JUN |
| Type of Article | Article |
| ISSN | 0248-8663 |
| Mots-clés | cardiovascular risk factors, guidelines, Screening, Systemic lupus erythematosus |
| Résumé | Purpose. - To develop French recommendations about screening and management of cardiovascular risk factors in systemic lupus erythematosus (SLE). Methods. - Thirty-nine experts qualified in internal medicine, rheumatology and nephrology have selected recommendations from a list developed based on evidence from the literature. For each recommendation, the level of evidence and the level of agreement among the experts were specified. Results. - Experts recommended an annual screening of cardiovascular risk factors in SLE. Statins should be. prescribed for primary prevention in SLE patients based on the level of LDL-cholesterol and the number of cardiovascular risk factors, considering SLE as an additional risk factor. For secondary prevention, experts have agreed on an LDL-cholesterol target of <0.7 g/L. Hypertension should be managed according to the 2013 European guidelines, using renin-angiotensin system blockers as first line agents in case of renal involvement. Aspirin can be prescribed in patients with high cardiovascular risk or with antiphospholipid antibodies. Conclusion. - These recommendations about the screening and management of cardiovascular risk factors in SLE can be expected to improve clinical practice uniformity and, in the longer term, to optimize the management of SLE patients. (C) 2014 Societe nationale francaise de medecine interne (SNFMI). Published by Elsevier Masson SAS. All rights reserved. |
| DOI | 10.1016/j.revmed.2014.10.009 |